+

WO2003013604A3 - Traitement des troubles metaboliques par les agonistes et les antagonistes de migenix - Google Patents

Traitement des troubles metaboliques par les agonistes et les antagonistes de migenix Download PDF

Info

Publication number
WO2003013604A3
WO2003013604A3 PCT/IB2002/003544 IB0203544W WO03013604A3 WO 2003013604 A3 WO2003013604 A3 WO 2003013604A3 IB 0203544 W IB0203544 W IB 0203544W WO 03013604 A3 WO03013604 A3 WO 03013604A3
Authority
WO
WIPO (PCT)
Prior art keywords
migenix
agonists
antagonists
activity
treatment
Prior art date
Application number
PCT/IB2002/003544
Other languages
English (en)
Other versions
WO2003013604A2 (fr
Inventor
John Lucas
Deno Dialynas
Kristen Briggs
Original Assignee
Genset Sa
John Lucas
Deno Dialynas
Kristen Briggs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa, John Lucas, Deno Dialynas, Kristen Briggs filed Critical Genset Sa
Priority to AU2002339213A priority Critical patent/AU2002339213A1/en
Publication of WO2003013604A2 publication Critical patent/WO2003013604A2/fr
Publication of WO2003013604A3 publication Critical patent/WO2003013604A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention a trait au domaine de la recherche métabolique, en particulier à la découverte de composés qui réduisent efficacement la masse corporelle et qui sont utilisés pour traiter les troubles et les maladies liés à l'obésité. Les troubles et les maladies liés à l'obésité que ces méthodes visent à traiter sont, notamment, l'hyperlipidémie, l'athérosclérose, l'insulinorésistance, le diabète et l'hypertension. L'invention concerne par ailleurs des méthodes d'identification et d'utilisation d'agonistes et d'antagonistes de l'activité de la protéine migenix, laquelle activité est sélectionnée dans le groupe constitué par la séparation de lipides, le métabolisme lipidique, et l'activité de type insuline.
PCT/IB2002/003544 2001-08-09 2002-08-06 Traitement des troubles metaboliques par les agonistes et les antagonistes de migenix WO2003013604A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002339213A AU2002339213A1 (en) 2001-08-09 2002-08-06 Migenix agonists and antagonists for use in the treatment of metabolic disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31138801P 2001-08-09 2001-08-09
US60/311,388 2001-08-09

Publications (2)

Publication Number Publication Date
WO2003013604A2 WO2003013604A2 (fr) 2003-02-20
WO2003013604A3 true WO2003013604A3 (fr) 2003-10-09

Family

ID=23206662

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/003544 WO2003013604A2 (fr) 2001-08-09 2002-08-06 Traitement des troubles metaboliques par les agonistes et les antagonistes de migenix

Country Status (2)

Country Link
AU (1) AU2002339213A1 (fr)
WO (1) WO2003013604A2 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10279500A (ja) * 1997-04-04 1998-10-20 Sumitomo Pharmaceut Co Ltd 肥満症治療剤
WO1999059618A1 (fr) * 1998-05-21 1999-11-25 Smithkline Beecham Corporation Acrp30r1l, homologue de acrp30 (proteine associee a un complement de l'adipocyte 30 kd)
WO2000020578A1 (fr) * 1998-10-06 2000-04-13 The Walter And Eliza Hall Institute Of Medical Research Procede de modulation de la survie cellulaire et reactifs utiles pour ce faire
EP1010432A1 (fr) * 1997-01-23 2000-06-21 Sumitomo Pharmaceuticals Company, Limited Remedes contre le diabete
EP1033134A1 (fr) * 1997-10-29 2000-09-06 Otsuka Pharmaceutical Co., Ltd. Compositions inhibant la proliferation des muscles lisses, procede de diagnostic de l'arteriosclerose et trousses correspondantes
WO2000068380A2 (fr) * 1999-05-11 2000-11-16 Incyte Genomics, Inc. Proteines de matrice extracellulaire associees a l'adhesion
WO2000073448A1 (fr) * 1999-05-27 2000-12-07 Zymogenetics, Inc. Homologue zacrp7 de proteine lie a un complement adipocyte
WO2001051645A1 (fr) * 2000-01-14 2001-07-19 Genset Tete globulaire obg3 et ses utilisations pour reduire la masse corporelle
WO2002018955A1 (fr) * 2000-09-01 2002-03-07 The Victoria University Of Manchester Essai de neuropathie par detection de p75ntr

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1010432A1 (fr) * 1997-01-23 2000-06-21 Sumitomo Pharmaceuticals Company, Limited Remedes contre le diabete
JPH10279500A (ja) * 1997-04-04 1998-10-20 Sumitomo Pharmaceut Co Ltd 肥満症治療剤
EP1033134A1 (fr) * 1997-10-29 2000-09-06 Otsuka Pharmaceutical Co., Ltd. Compositions inhibant la proliferation des muscles lisses, procede de diagnostic de l'arteriosclerose et trousses correspondantes
WO1999059618A1 (fr) * 1998-05-21 1999-11-25 Smithkline Beecham Corporation Acrp30r1l, homologue de acrp30 (proteine associee a un complement de l'adipocyte 30 kd)
WO2000020578A1 (fr) * 1998-10-06 2000-04-13 The Walter And Eliza Hall Institute Of Medical Research Procede de modulation de la survie cellulaire et reactifs utiles pour ce faire
WO2000068380A2 (fr) * 1999-05-11 2000-11-16 Incyte Genomics, Inc. Proteines de matrice extracellulaire associees a l'adhesion
WO2000073448A1 (fr) * 1999-05-27 2000-12-07 Zymogenetics, Inc. Homologue zacrp7 de proteine lie a un complement adipocyte
WO2001051645A1 (fr) * 2000-01-14 2001-07-19 Genset Tete globulaire obg3 et ses utilisations pour reduire la masse corporelle
WO2002018955A1 (fr) * 2000-09-01 2002-03-07 The Victoria University Of Manchester Essai de neuropathie par detection de p75ntr

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199901, Derwent World Patents Index; Class B04, AN 1999-005177, XP002246263 *

Also Published As

Publication number Publication date
WO2003013604A2 (fr) 2003-02-20
AU2002339213A1 (en) 2003-02-24

Similar Documents

Publication Publication Date Title
WO2004110376A3 (fr) Antagonistes de ccr-2 permettant de traiter une douleur neuropathique
HUS1600042I1 (hu) Anti-CS1 antitestek terápiás alkalmazása
WO2005102387A3 (fr) Utilisation therapeutique des anticorps anti-cs1
WO2004037861A3 (fr) Anticorps de neutralisation diriges contre gdf-8 et utilisations de ceux-ci
WO2004047760A3 (fr) Nouveaux composes chimiques
WO2003057666A3 (fr) Inhibiteurs de la dipeptidyl peptidase iv
AU2002327378A1 (en) Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation
WO2005103041A3 (fr) Traitement des troubles du systeme nerveux central au moyen de modulateurs cibles du snc
WO2003057698A3 (fr) Composes spiroazacycliques utilises comme modulateurs du recepteur de monoamine
WO2005030240A3 (fr) Produits vegf-c ou vegf-d et methodes de stimulation des cellules souches neurales
WO2004056307A3 (fr) Traitement de maladie par le biais d'inhibiteurs de peptides antimicrobiens
EP1251126A3 (fr) Derives de benzenesulfonyle a substitution fluor pour le traitment d'inflammation
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
WO2007087424A3 (fr) Procede destine a traiter des troubles lies a kcnq a l’aide de composes organozinc
WO2008083169A3 (fr) Compositions et procédés pour le traitement de troubles immunologiques
WO2003013578A8 (fr) Traitement des troubles metabolique au moyen d'agonistes et d'antagonistes d'omoxine
TW200510437A (en) Phosphinane compound with immunomodulating activity
AU2003273250A1 (en) Triazaspiro compounds useful for treating or preventing pain
WO2003013604A3 (fr) Traitement des troubles metaboliques par les agonistes et les antagonistes de migenix
WO2003013585A8 (fr) Agonistes et antagonistes de la mifaxine convenant au traitement de troubles du metabolisme au moyen
WO2004043365A3 (fr) Methode de traitement de l'ejaculation precoce chez les humains
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
WO2003095485A3 (fr) Polynucleotides et polypeptides krib et utilisations de ceux-ci dans le traitement de troubles metaboliques
WO2007067516A3 (fr) Myelome multiple
EP1597234A4 (fr) Nouveaux composes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载